FILING ANALYSIS · THURSDAY, NOVEMBER 12
Parabilis Medicines, Inc. PBLS — 8-K: Results of Operations and Financial Condition
positive
Parabilis Medicines reported a 72.2% objective response rate for zolucatetide in desmoid tumors and has $1.1 billion in cash to fund operations into 2030, with several clinical trials and collaborations underway, including a planned Phase 3 registrational trial in desmoid tumors and a clinical collaboration with Revolution Medicines in MSS CRC.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →